Canaccord Adams Maintains a 'Buy' on Protalix BioTherapeutics (PLX); Cerezyme Supply on Track, See More Uplyso EAP Uptake
Tweet Send to a Friend
Canaccord Adams maintains a 'Buy' on Protalix BioTherapeutics (NYSE Amex: PLX), price target $13.
Canaccord analyst says, "Genzyme (Nasdaq: GENZ) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Genzyme (Nasdaq: GENZ) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
